These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 10908006)
1. A descriptive analysis of participant characteristics and patterns of substance use in the CSAT methamphetamine treatment project: the first six months. Reiber C; Galloway G; Cohen J; Hsu JC; Lord RH J Psychoactive Drugs; 2000; 32(2):183-91. PubMed ID: 10908006 [TBL] [Abstract][Full Text] [Related]
2. The CSAT methamphetamine treatment program: research design accommodations for "real world" application. Huber A; Lord RH; Gulati V; Marinelli-Casey P; Rawson R; Ling W J Psychoactive Drugs; 2000; 32(2):149-56. PubMed ID: 10908002 [TBL] [Abstract][Full Text] [Related]
3. Methamphetamine abuse: issues for special populations. Freese TE; Obert J; Dickow A; Cohen J; Lord RH J Psychoactive Drugs; 2000; 32(2):177-82. PubMed ID: 10908005 [TBL] [Abstract][Full Text] [Related]
4. A multisite study of the effectiveness of methamphetamine treatment: an initiative of the Center for Substance Abuse Treatment. Herrell JM; Taylor JA; Gallagher C; Dawud-Noursi S J Psychoactive Drugs; 2000; 32(2):143-7. PubMed ID: 10908001 [TBL] [Abstract][Full Text] [Related]
5. Treatment-as-usual in the methamphetamine treatment project. Galloway GP; Marinelli-Casey P; Stalcup J; Lord R; Christian D; Cohen J; Reiber C; Vandersloot D J Psychoactive Drugs; 2000; 32(2):165-75. PubMed ID: 10908004 [TBL] [Abstract][Full Text] [Related]
6. The CSAT methamphetamine treatment project: what are we trying to accomplish? Anglin MD; Rawson RA J Psychoactive Drugs; 2000; 32(2):209-10. PubMed ID: 10908009 [No Abstract] [Full Text] [Related]
8. Moving research into community settings in the CSAT methamphetamine treatment project: the coordinating center perspective. Rawson RA; McCann MJ; Huber A; Marinelli-Casey P; Williams L J Psychoactive Drugs; 2000; 32(2):201-8. PubMed ID: 10908008 [TBL] [Abstract][Full Text] [Related]
9. When treatment meets research: clinical perspectives from the CSAT Methamphetamine Treatment Project. Obert JL; Brown AH; Zweben J; Christian D; Delmhorst J; Minsky S; Morrisey P; Vandersloot D; Weiner A J Subst Abuse Treat; 2005 Apr; 28(3):231-7. PubMed ID: 15857723 [TBL] [Abstract][Full Text] [Related]
10. Conducting trials in community settings: the provider perspective. Zweben JE; Cohen JB; Obert J; Vandersloot D; Marinelli-Casey P J Psychoactive Drugs; 2000; 32(2):193-9. PubMed ID: 10908007 [TBL] [Abstract][Full Text] [Related]
11. A comparison of injecting and noninjecting methamphetamine users. Domier CP; Simon SL; Rawson RA; Huber A; Ling W J Psychoactive Drugs; 2000; 32(2):229-32. PubMed ID: 10908012 [TBL] [Abstract][Full Text] [Related]
12. [Clinical characteristics of dappou herb use--disorder patients at the drug dependence clinic: a comparison with methamphetamine use-disorder patients]. Tanibuchi Y; Matsumoto T; Kobayashi O; Wada K Seishin Shinkeigaku Zasshi; 2013; 115(5):463-76. PubMed ID: 23855225 [TBL] [Abstract][Full Text] [Related]
13. Correlates of outpatient drug treatment drop-out among methamphetamine users. Maglione M; Chao B; Anglin MD J Psychoactive Drugs; 2000; 32(2):221-8. PubMed ID: 10908011 [TBL] [Abstract][Full Text] [Related]
14. Treatment response by primary drug of abuse: does methamphetamine make a difference? Luchansky B; Krupski A; Stark K J Subst Abuse Treat; 2007 Jan; 32(1):89-96. PubMed ID: 17175402 [TBL] [Abstract][Full Text] [Related]
15. Methamphetamine users entering treatment: characteristics of the methamphetamine treatment project sample. Christian DR; Huber A; Brecht ML; McCann MJ; Marinelli-Casey P; Lord RH; Reiber C; Lu TH; ; Galloway GP Subst Use Misuse; 2007; 42(14):2207-22. PubMed ID: 18098001 [TBL] [Abstract][Full Text] [Related]
16. The matrix model of outpatient stimulant abuse treatment: history and description. Obert JL; McCann MJ; Marinelli-Casey P; Weiner A; Minsky S; Brethen P; Rawson R J Psychoactive Drugs; 2000; 32(2):157-64. PubMed ID: 10908003 [TBL] [Abstract][Full Text] [Related]
17. Predictors of relapse after treatment for methamphetamine use. Brecht ML; von Mayrhauser C; Anglin MD J Psychoactive Drugs; 2000; 32(2):211-20. PubMed ID: 10908010 [TBL] [Abstract][Full Text] [Related]
18. Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: a national drug abuse treatment clinical trials network study. Petry NM; Peirce JM; Stitzer ML; Blaine J; Roll JM; Cohen A; Obert J; Killeen T; Saladin ME; Cowell M; Kirby KC; Sterling R; Royer-Malvestuto C; Hamilton J; Booth RE; Macdonald M; Liebert M; Rader L; Burns R; DiMaria J; Copersino M; Stabile PQ; Kolodner K; Li R Arch Gen Psychiatry; 2005 Oct; 62(10):1148-56. PubMed ID: 16203960 [TBL] [Abstract][Full Text] [Related]
19. The NIDA Methamphetamine Clinical Trials Group: a strategy to increase clinical trials research capacity. Elkashef A; Rawson RA; Smith E; Pearce V; Flammino F; Campbell J; Donovick R; Gorodetzky C; Haning W; Mawhinney J; McCann M; Weis D; Williams L; Ling W; Vocci F Addiction; 2007 Apr; 102 Suppl 1():107-13. PubMed ID: 17493059 [TBL] [Abstract][Full Text] [Related]
20. Results of the ACSUS for pediatric AIDS patients: utilization of services, functional status, and social severity. Fahs MC; Waite D; Sesholtz M; Muller C; Hintz EA; Maffeo C; Arno P; Bennett C Health Serv Res; 1994 Dec; 29(5):549-68. PubMed ID: 8002349 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]